Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cryoport, Inc.CYRX · Entity 5125 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cryoport, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,052 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,350 · Balance 69,052 F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2033-06-05 | Direct | 16,077 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,077 · Balance 16,077 F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 01:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 16,077 | $0.00 Strike: $15.70 | $0.00 |
DisclosureSEC source: 0001104659-26-071508 · tm2617191-3_4seq1.xml · derivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,077 Underlying: Common Stock · 16,077 shares Expires 2033-06-05 F2 · derivative.exercise_date: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 01:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 10,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071508 · tm2617191-3_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,052 F1 · security: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:27 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 41,098 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058269 · tm2517578-4_4seq1.xml · derivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,098 Underlying: Common Stock · 41,098 shares Expires 2032-06-06 F2 · derivative.exercise_date: 1/12th of the options vest on the 6th of the month for twelve months beginning July 6, 2025. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:27 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 23,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058269 · tm2517578-4_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,702 F1 · security: Reflects grant of restricted stock rights that vest in full on June 6, 2026, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on June 6, 2026, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063963 · tm2415098-2_4seq1.xml · derivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063963 · tm2415098-2_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,488 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 12, 2023 Filed May 16, 2023 23:27 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 15,125 | $0.00 Strike: $20.05 | $0.00 |
DisclosureSEC source: 0001104659-23-061519 · tm2316016-2_4seq1.xml · derivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,125 Underlying: Common Stock · 15,125 shares Expires 2030-05-12 F2 · derivative.exercise_date: 1/12th of the options vest on the 12th of the month for twelve months beginning June 12, 2023. Read SEC document |
| May 12, 2023 Filed May 16, 2023 23:27 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 8,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-061519 · tm2316016-2_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,643 F1 · security: Reflects grant of restricted stock rights that vest in full on May 12, 2024, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 12, 2024, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| April 30, 2022 Filed May 4, 2022 00:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055436 · tm2214402-2_4seq1.xml · derivative · entry 3 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. F2 · derivative.expiration_date: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. Read SEC document |
| April 30, 2022 Filed May 4, 2022 00:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 2,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055436 · tm2214402-2_4seq1.xml · nonDerivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 13,981 | $0.00 Strike: $22.56 | $0.00 |
DisclosureSEC source: 0001104659-22-055436 · tm2214402-2_4seq1.xml · derivative · entry 4 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,981 Underlying: Common Stock · 13,981 shares Expires 2029-04-29 F3 · derivative.exercise_date: 1/12th of the options vest on the 30th of the month for twelve months beginning May 30, 2022. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 7,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055436 · tm2214402-2_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,830 F1 · security: Reflects grant of restricted stock rights that vest in full on April 29, 2023, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on April 29, 2023, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 20:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 11,217 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001104659-21-129023 · tm2130870d1_4.xml · derivative · entry 7 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,217 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F5 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the twelve (12) months beginning on 05/02/2019. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 20:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 5,317 | $76.24 | $405,390.94 |
DisclosureSEC source: 0001104659-21-129023 · tm2130870d1_4.xml · nonDerivative · entry 5 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.91 to $76.63, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 20:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 5,900 | $75.29 | $444,205.10 |
DisclosureSEC source: 0001104659-21-129023 · tm2130870d1_4.xml · nonDerivative · entry 4 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,944 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.90 to $75.89, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 20:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 11,217 | $14.35 | $160,963.95 |
DisclosureSEC source: 0001104659-21-129023 · tm2130870d1_4.xml · nonDerivative · entry 3 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 3,783 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001104659-21-129023 · tm2130870d1_4.xml · derivative · entry 6 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,217 Underlying: Common Stock · 3,783 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F5 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the twelve (12) months beginning on 05/02/2019. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 3,783 | $75.17 | $284,385.13 |
DisclosureSEC source: 0001104659-21-129023 · tm2130870d1_4.xml · nonDerivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.90 to $75.40, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 3,783 | $14.35 | $54,286.05 |
DisclosureSEC source: 0001104659-21-129023 · tm2130870d1_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 10,000 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001104659-21-120779 · tm2128815-1_4seq1.xml · derivative · entry 3 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F3 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the twelve (12) months beginning on 05/02/2019. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 10,000 | $70.17 | $701,722.00 |
DisclosureSEC source: 0001104659-21-120779 · tm2128815-1_4seq1.xml · nonDerivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.65 to $70.47, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 10,000 | $14.35 | $143,500.00 |
DisclosureSEC source: 0001104659-21-120779 · tm2128815-1_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:45 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 574 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001104659-21-113455 · tm2127086-1_4seq1.xml · derivative · entry 3 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 574 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F3 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the twelve (12) months beginning on 05/02/2019. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:45 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 574 | $67.18 | $38,561.66 |
DisclosureSEC source: 0001104659-21-113455 · tm2127086-1_4seq1.xml · nonDerivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.41, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:45 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 574 | $14.35 | $8,236.90 |
DisclosureSEC source: 0001104659-21-113455 · tm2127086-1_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 100 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001104659-21-087640 · tm2120991-1_4seq1.xml · derivative · entry 6 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,574 Underlying: Common Stock · 100 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F3 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the next twelve (12) months beginning on 05/02/2019. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 100 | $67.03 | $6,703.18 |
DisclosureSEC source: 0001104659-21-087640 · tm2120991-1_4seq1.xml · nonDerivative · entry 4 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.03 to $67.05, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 100 | $14.35 | $1,435.00 |
DisclosureSEC source: 0001104659-21-087640 · tm2120991-1_4seq1.xml · nonDerivative · entry 3 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 9,326 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001104659-21-087640 · tm2120991-1_4seq1.xml · derivative · entry 5 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,674 Underlying: Common Stock · 9,326 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F3 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the next twelve (12) months beginning on 05/02/2019. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 9,326 | $67.09 | $625,690.67 |
DisclosureSEC source: 0001104659-21-087640 · tm2120991-1_4seq1.xml · nonDerivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.4850, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 9,326 | $14.35 | $133,828.10 |
DisclosureSEC source: 0001104659-21-087640 · tm2120991-1_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 12,850 | $0.00 Strike: $9.73 | $0.00 |
DisclosureSEC source: 0001104659-21-084735 · tm2120565d1_4.xml · derivative · entry 4 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,850 shares Expires 2029-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F4 · derivative.exercise_date: 2,850 of the options vest on January 17, 2019 and 1/4 of the remaining 10,000 options vest on the 17th of each month for four months beginning on 2/17/2019. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 5,544 | $66.04 | $366,116.34 |
DisclosureSEC source: 0001104659-21-084735 · tm2120565d1_4.xml · nonDerivative · entry 3 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.995 to $66.11, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 7,306 | $65.53 | $478,764.37 |
DisclosureSEC source: 0001104659-21-084735 · tm2120565d1_4.xml · nonDerivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,171 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.90 to $65.86, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 12,850 | $9.73 | $125,030.50 |
DisclosureSEC source: 0001104659-21-084735 · tm2120565d1_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 10,000 | $0.00 Strike: $9.73 | $0.00 |
DisclosureSEC source: 0001104659-21-078924 · tm2119287d1_4.xml · derivative · entry 6 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2029-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F3 · derivative.exercise_date: 1/36 of the options originally granted vested on the 4th day of each month for the twelve months beginning on February 4, 2019. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 10,000 | $61.23 | $612,320.00 |
DisclosureSEC source: 0001104659-21-078924 · tm2119287d1_4.xml · nonDerivative · entry 4 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.00 to $61.84, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 10,000 | $9.73 | $97,300.00 |
DisclosureSEC source: 0001104659-21-078924 · tm2119287d1_4.xml · nonDerivative · entry 3 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 10,000 | $0.00 Strike: $9.73 | $0.00 |
DisclosureSEC source: 0001104659-21-078924 · tm2119287d1_4.xml · derivative · entry 5 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2029-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F3 · derivative.exercise_date: 1/36 of the options originally granted vested on the 4th day of each month for the twelve months beginning on February 4, 2019. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 10,000 | $60.02 | $600,198.00 |
DisclosureSEC source: 0001104659-21-078924 · tm2119287d1_4.xml · nonDerivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.90 to $60.31, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:48 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 10,000 | $9.73 | $97,300.00 |
DisclosureSEC source: 0001104659-21-078924 · tm2119287d1_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021. Read SEC document |
| April 30, 2021 Filed May 7, 2021 22:42 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantRestricted Stock Rights · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-063250 · tm2115610d3_4.xml · derivative · entry 2 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,708 Underlying: Common Stock · 2,708 shares Expires 2022-04-30 F2 · derivative.exercise_price: Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| April 30, 2021 Filed May 7, 2021 22:42 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption to purchase common stock · Derivative | 5,416 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001104659-21-063250 · tm2115610d3_4.xml · derivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 5,416 shares Expires 2028-04-30 F1 · derivative.exercise_date: 1/12th of options vest on the 30th of the month for twelve months beginning May 30, 2021. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 229 | $50.24 | $11,504.96 |
DisclosureSEC source: 0001104659-21-046126 · tm2111959d1_form4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:44 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 261 | $44.11 | $11,512.71 |
DisclosureSEC source: 0001104659-21-000869 · tm211709d1_4seq1.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,398 Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 15:41 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 240 | $47.82 | $11,476.80 |
DisclosureSEC source: 0001104659-20-111502 · tm2032297d2_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,137 Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 20:58 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 389 | $29.54 | $11,491.06 |
DisclosureSEC source: 0001104659-20-079772 · tm2023884-1_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,897 Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $18.02 | $0.00 |
DisclosureSEC source: 0001104659-20-057096 · tm2018763d1_4.xml · derivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-05-01 F1 · derivative.exercise_date: 1/12 of these options vest and become exercisable on the 1st of each month for twelve (12) months beginning on 06/01/2020. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 20:35 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 706 | $16.29 | $11,500.74 |
DisclosureSEC source: 0001104659-20-041885 · tm2014753-2_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,508 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 15:30 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 704 | $16.34 | $11,503.36 |
DisclosureSEC source: 0001104659-20-000618 · tm201102d1_4.xml · nonDerivative · entry 1 HANCOCK DANIEL M · CIK 0001764017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,802 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.